1 May 2023: Abstract submission open
30 June 2023: EXTENDED abstract submission deadline
To ensure that the best and most current research is presented, a large proportion of the programme is dedicated to selected abstracts. A panel of international moderators reviews the abstracts so that every abstract receives at least 3 reviewer scores.
All accepted abstracts will be published in our journal, Human Gene Therapy, if authors consent to this.
Once you have registered for the event, you can then submit your abstract via your online ESGCT account.
Make sure your abstract is submitted on time and in the right format by following these simple steps:
Your abstract should be no more than 500 words in length and should be in English.
Abstracts should be continuous text and not split up into subheadings such as "introduction, methods, results".
Keep your title concise and informative and only use capital letters for the beginning of a sentence or for an acronym/name. Do not use CAPITAL LETTERS for your entire title.
The names of all authors associated with the abstract must be listed, and a presenting author must be identified.
All authors' names should be listed as initials and surname. Only the first letter of the surname should be capitalised, not the full surname (i.e. JR Smith, not JR SMITH)
Addresses should be in the following format: Group, Department/Institute, Organisation, Town/City, Postcode, Country.
Do not include acknowledgements or references in your abstracts – these will be counted in your word count.
Select the subject area that best fits your abstract as this is a guide for review allocation.
Please ensure that the email provided when submitting the abstract will still be valid in the lead up to and during the event as we will need to contact you about the outcome of your submission.
You must read and agree to the Abstract Submission Terms & Conditions before submitting your abstract.
What happens after you have submitted?
Your abstract will be sent for review by a panel of international evaluators. Every abstract receives at least 3 reviewer scores. You will be notified of the outcome by email in mid-September. Please note the notification email will be sent to the email address given when you submitted your abstract.
If you have not received notification by the late-September, please check your spam/junk or contact the ESGCT Office immediately.
If you wish to withdraw your abstract after submission you must request this as soon as possible. Please be aware that if abstract withdrawal requests are received at short notice, it may not be possible to remove them from the printed Congress materials or the Human Gene Therapy publication.
The ESGCT Outstanding Achievement Award and Young Investigator Award will be handed out in the Presidential Symposium. See our website for further details for how to nominate an ESGCT Member for these awards.
ESGCT Travel Grants are awarded to the highest scoring abstracts. If you wish to be considered for a Travel Grant, please tick the relevant box when submitting your abstract.
Acceptance of Presentation
All notified abstract presenters are required to accept their presentation as instructed in their notification email.
Late Breaking Abstract Submissions
ESGCT will accept Late Breaking Abstract submissions until the end of August only for abstracts with brand new data which has not been presented or published before.
For all questions regarding the abstract submission process, please contact Gaëlle Jamar.